H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Kamada (KMDA) today and set a price target of $11. The company’s shares closed yesterday at $5.54.
Fein wrote:
“Our price target of $11/share is based on an equally weighted composite of: (a) $14.26/share, as a 35x multiple of taxed and diluted FY23 GAAP EPS of $0.84 discounted back to and (b) an NPV of $8.1/share (discount rate 12%, growth rate 2%). Risks to our investment thesis and target price include: (1) failure of AAT (IV and IH) to achieve peak commercial revenue estimates in our model (due to market size, penetration rates, and/ or pricing); (2) failure of IH-AAT in clinical studies; (3) failure of IH-AAT to secure regulatory approval; and (4) other potential pipeline failures.”
According to TipRanks.com, Fein is a 2-star analyst with an average return of 0.4% and a 38.9% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and ACADIA Pharmaceuticals Inc.
Currently, the analyst consensus on Kamada is a Moderate Buy with an average price target of $9.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.70 and a one-year low of $4.63. Currently, Kamada has an average volume of 41.51K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kamada Ltd. engages in the development and production of pharmaceutical products. It operates through the following business segments: Proprietary Products, and Distribution. The Proprietary Products segment develops, manufactures and sells plasma-derived protein therapeutics products. The Distribution segment supplies plasma based products for clinical use.
